Learn how the OncoDiscover CTC test detects circulating tumor cells from blood to support cancer monitoring, treatment response evaluation, and follow-up care. Innovation at the core. A small blood test. A big impact. The OncoDiscover® CTC Test is India's first indigenously developed, patented in-vitro diagnostic test to get DCG(I) approval for marketing in India. Book a test This test is a highly specific and sensitive test that can detect, capture and enumerate Circulating Tumor Cells in very low volume of blood. Circulating Tumor Cells are a telltale signature of cancer metastasis. Which cancers are tested? The OncoDiscover® CTC Test is designed to detect Carcinomas which are the most prevalent form of cancer in the world. Carcinomas account for nearly 80% of all cancer cases in the world. Book a test OncoDiscover® CTC Test empowers oncologists to make better treatment decisions for improved outcomes See what renowned medical oncologist -Dr Nirmal Raut has to say → Interpreting the OncoDiscover® CTC Test Report As cancer cells multiply to form a tumor, they continue to change – becoming more and more different from each other. Hence cancer of one individual is different from that of another, even though the tissue of origin may be same. Circulating Tumor Cells (CTC) number is a personal indicator of a patient's cancer status and must not be used to compare with data of other patients. Circulating Tumor Cells (CTC) are indicative of the real time status of cancer. Based on previous results, it becomes a useful tool to monitor progression. Hence, it is important to do the test on regular intervals to monitor the condition with respect to the initial baseline number. Circulating Tumor Cells (CTC) are indicative of the real time status of cancer. Based on previous results, it becomes a useful to tool to monitor progression. Hence, it is important to do the test on regular intervals to monitor the condition with respect to the initial baseline number. OncoDiscover® CTC Test Platform The OncoDiscover® CTC Test is built on the backbone of a proprietary multicomponent in-vitro diagnostic kit (OncoViu® Kit) for capturing Circulating Tumor Cells from cancer patient blood. Book a test *Ref: Qayyumi B, Oral Surg Oral Med Oral Pathol Oral Radiol. 2022;134(1):73-83; Validation Data* 94.32% Sensitivity 98% Specificity 95.17% Accuracy Our Numbers 11000+ Tests Performed 10000+ Patients Served 450+ Doctors Trust Us CTC and Minimal Residual Disease (MRD) CTC captured from blood sample of Breast Cancer patient CTC Cluster captured from blood sample of Mixed Mullerian Cancer patient Detection of Circulating Tumor Cells (CTC) allows monitoring of minimal residual disease and subsequent metastatic progression. Early therapeutic intervention on the basis of liquid biopsy assessments might improve patient outcomes. How OncoDiscover detects MRD? The OncoDiscover® Liquid Biopsy Test detects and characterizes minimal residual disease (MRD) by identifying tumor cells shed from the primary lesion. Useful even when there are no clinical or radiological signs of metastasis or residual tumor cells. Enables monitoring of circulating tumor cells (CTCs) during post-treatment follow-up. Allows earlier detection of disease relapse compared to standard radiological imaging. Assesses PD-L1 and Her2 expression on CTCs to guide targeted therapy. Fighting cancer. One cell at a time. One in a billion cells. Even a single tumor cell can cause cancer relapse and can lead to metastasis (spread of cancer). OncoDiscover® CTC Test detects, with pinpoint accuracy, those pesky cells whose presence, even a single one of them, leads to the spread of cancer even after the patient’s treatment has been completed and the patient seems to have recovered. Cost-effective The OncoDiscover® CTC Test has been developed with a goal of making it affordable and accessible to everyone who is in need of it. It is 50% cheaper than any other test to diagnose cancer cells. Time Saving At OncoDiscover® laboratory the diagnostic test are run on the blood samples of the patients. Typically a complete run cycle is completed within a weeks time followed by analysis by scientific experts. Accurate The OncoDiscover® CTC Test can identify pesky tumor cells amongst billions of cells in the blood samples from the patients. It is as accuarate as counting one in a billion cells from the blood sample. Safe The OncoDiscover® CTC Test is absolutely safe. Only 10 ml of patients blood sample is collected and subject to the diagnostic runs. Patients don’t need to through any other tests including that involving radiations. Convenient The OncoDiscover® CTC Test is a simple blood test. Just book the CTC Test online or through a phone call. Our registered phlebotomists can collect the blood samples from patient’s home. Pain-free The patient doesn’t have to go through any medical procedure or go through any tissue biopsy. All that it needs is patients blood samples - ensuring its physically and emotionally pain-free for the patient. Who should get tested? High Risk Factors Smoking / Chewing Tobacco, Alcohol, Pollution, Work Hazard, Age, and people with family history of cancer. Individuals with Cancer Symptoms Unusual bleeding, Change in bowel habits, Unusual lumps, Nagging cough Individuals taking Cancer Treatment Chemotherapy, Radiation, Surgery, Hormone Therapy. Individuals Post Cancer Treatment To monitor the Chances of cancer relapse Licences License No: MFG / IVD2019 / 000004 License Name: MD 29 – Permission to import or manufacture new in-vitro diagnostic medical device. Licensing Authority: Central Drug Standards Control Organisation (CDSCO), New Delhi, India. License No: MFG / IVD2019 / 000031 License Name: MD 9 – License to Manufacture for Sale or for Distribution of Class C or Class D medical device. Licensing Authority: Central Drug Standards Control Organisation (CDSCO), New Delhi, India. Accreditations FAQS Frequently asked questions Answers to commonly asked questions about Actorius and our offerings. What kind of cancers are detected by the test? The OncoDiscover® Circulating Tumor Cells Test can detect CTCs originating from Epithelial Cancers (Carcinomas). Some major Carcinomas are: - Head & Neck, - Breast, Lung, - Colorectal, - Prostate, - Cervical, - Gall Bladder, etc. These constitute more than 70% of all the Cancers of the world. However, the OncoDiscover® Circulating Tumor Cells Test does not detect Sarcoma, Melanoma, Lymphoma and Leukemia. Please contact us to see if you qualify for this test. Who should get tested? Patients diagnosed with epithelial cancers: The OncoDiscover® CTC Test can be used to understand the spread of cancer in patients diagnosed with epithelial cancers. Patients undergoing therapy: The OncoDiscover® CTC Test can be used to monitor CTC levels in patients undergoing therapy to understand the effectiveness of the therapy. Patients in remission: The OncoDiscover® CTC Test can be used to monitor CC levels in patients to detect cancer relapse at the earliest stage. Patients with suspected but undetectable epithelial cancers: In many cases, doctors may suspect a cancer due to symptoms or preliminary testing but may not be able to conclusively diagnose a cancer. The OncoDiscover® CTC Test can be used to detect presence of cancer cells in the blood as conclusive evidence of metastasis Is the test safe? The OncoDiscover® CTC Test is a simple and safe blood test. In medical terms, it is an in-vitro diagnostic test, which is essentially a test done on samples such as blood taken from human body. The test requires withdrawing a low volume (5ml) of blood from the patient. The blood will be withdrawn by a trained phlebotomist or a nurse. What should be the frequency of testing? We recommend testing once every 3 months to understand the real-time status of the cancer in your body. For patients currently undergoing therapy, the Oncologist will decide on the timepoint and frequency of testing. Do I need to fast before the blood test? There are no special preparations required for getting tested. You do not need to fast or avoid any food before the test. Do I need to stop any medicine before the blood test? There are no special preparations required for getting tested. You do not need to stop any medicine before the blood test. No cancer cells were found in my test. Am I cancer-free? If no cancer cells were detected by the OncoDiscover® CTC Test, it only means that at present cancer cells are not present in your bloodstream. A cancer cell which may be dormant currently may express itself later. It is essential to continuously monitor the status of cancer. What kind of therapy should I undergo based on the test results? Only an Oncologist is qualified to decide on the course of action based on the test results. We shall not offer any advice or consultation on cancer therapy. Can this predict future onset of cancer? This test is a real time test of cancer status in the body. This test does not determine the future status of cancer. Know More Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Book the OncoDiscover CTC test easily online and offline for cancer monitoring and follow-up care through advanced circulating tumor cell detection. Test Booking Book your test, from anywhere. Professional blood collection at your doorstep. Choose how you'd like to book — online in minutes, or offline with personal assistance. ISO Certified Lab DCGI approved test Home sample collection Report in 7–10 Working Days End-to-end process How it works — at a glance 1 Book online or offline Choose your channel 2 Fill TRF form Online or in-person 3 Payment confirmed Online/ Link / QR / Cash 4 Sales person confirms Scheduling & details 5 Phlebo visits home Sample collection 6 Sample to lab Dispatched securely 7 Report delivered TAT = 7 working days Choose Booking Method Two ways to get started Both paths lead to the same expert care — pick what's most convenient for you. Online Booking Book online, we handle the rest Complete your Test Request Form and payment entirely online. Our sales team will reach out, verify your details, and schedule a doorstep collection at your convenience. Step-by-step journey 1 Fill the online TRF form Submit your Test Request Form with all patient and clinical details through our secure online portal. 2 Complete payment online Pay securely through our online payment gateway to instantly confirm your booking. 3 Sales person contacts you Our representative calls to verify your details and schedule your preferred collection slot. You may be asked to fill an offline TRF Even after completing the online form and payment, our sales person or phlebotomist may request you to fill a physical TRF at the time of blood collection — for verification or any additional clinical details required. 4 Phlebotomist visits your home Our trained phlebotomist comes to your doorstep to collect the blood sample. If instructed by the sales person, they will also collect the offline TRF or any other required documents. 5 Sample dispatched to lab Your sample is securely packaged and sent to our accredited laboratory for processing. Book a test online Offline / Contact us Share your details, we'll take it from there Fill a simple contact form and a dedicated sales person — assigned based on your location — will handle everything from the TRF to payment and scheduling. Step-by-step journey 1 Fill the contact form Submit your name, location, and contact details through our short offline enquiry form below. 2 Sales person assigned to you Based on your location, a dedicated sales representative is assigned and will contact you promptly. 3 Details collected & TRF filled Your sales person gathers all clinical and patient details and guides you through completing the Test Request Form (TRF). 4 Payment arranged Your representative will share a convenient payment option suited to you. Payment Links UPI / QR Code 5 Phlebotomist visits your home Our trained phlebotomist arrives at your doorstep for sample collection. If instructed by the sales person, they will also collect the TRF or any other required documents. 6 Sample dispatched to lab Your sample is securely packaged and sent to our accredited laboratory for processing. Book a test offline Report delivery applies to both booking paths — After your sample reaches our lab, your detailed diagnostic report will be delivered within 7 working days via the email shared by you in the TRF or online form. Common Questions Things patients often ask Answers to commonly asked questions of patients about booking the test. What kind of cancers are detected by the test? The OncoDiscover® Circulating Tumor Cells Test can detect CTCs originating from Epithelial Cancers (Carcinomas). Some major Carcinomas are: - Head & Neck, - Breast, Lung, - Colorectal, - Prostate, - Cervical, - Gall Bladder, etc. These constitute more than 70% of all the Cancers of the world. However, the OncoDiscover® Circulating Tumor Cells Test does not detect Sarcoma, Melanoma, Lymphoma and Leukemia. Please contact us to see if you qualify for this test. Who should get tested? Patients diagnosed with epithelial cancers: The OncoDiscover® CTC Test can be used to understand the spread of cancer in patients diagnosed with epithelial cancers. Patients undergoing therapy: The OncoDiscover® CTC Test can be used to monitor CTC levels in patients undergoing therapy to understand the effectiveness of the therapy. Patients in remission: The OncoDiscover® CTC Test can be used to monitor CC levels in patients to detect cancer relapse at the earliest stage. Patients with suspected but undetectable epithelial cancers: In many cases, doctors may suspect a cancer due to symptoms or preliminary testing but may not be able to conclusively diagnose a cancer. The OncoDiscover® CTC Test can be used to detect presence of cancer cells in the blood as conclusive evidence of metastasis Is the test safe? The OncoDiscover® CTC Test is a simple and safe blood test. In medical terms, it is an in-vitro diagnostic test, which is essentially a test done on samples such as blood taken from human body. The test requires withdrawing a low volume (5ml) of blood from the patient. The blood will be withdrawn by a trained phlebotomist or a nurse. What should be the frequency of testing? We recommend testing once every 3 months to understand the real-time status of the cancer in your body. For patients currently undergoing therapy, the Oncologist will decide on the timepoint and frequency of testing. Do I need to fast before the blood test? There are no special preparations required for getting tested. You do not need to fast or avoid any food before the test. Do I need to stop any medicine before the blood test? There are no special preparations required for getting tested. You do not need to stop any medicine before the blood test. No cancer cells were found in my test. Am I cancer-free? If no cancer cells were detected by the OncoDiscover® CTC Test, it only means that at present cancer cells are not present in your bloodstream. A cancer cell which may be dormant currently may express itself later. It is essential to continuously monitor the status of cancer. What kind of therapy should I undergo based on the test results? Only an Oncologist is qualified to decide on the course of action based on the test results. We shall not offer any advice or consultation on cancer therapy. Can this predict future onset of cancer? This test is a real time test of cancer status in the body. This test does not determine the future status of cancer. Why might I need to fill an offline TRF if I booked online? The physical TRF allows our team to capture additional clinical details or verify information at the time of collection, ensuring accurate lab processing. Can I pay in cash for an offline booking? Yes. For offline bookings, your assigned sales person will offer payment via link, QR code, or cash — whichever is most convenient for you. How will I receive my report? Reports are delivered within 7 working days via email provided by you during booking or in the TRF. Is my personal and clinical data secure? Absolutely. All data submitted through our portal is encrypted and handled in strict accordance with patient confidentiality guidelines. Can I reschedule my collection appointment? Yes. Contact your assigned sales person directly and they will reschedule your home collection to a time that works better for you. Know More Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test now

Contact the team of OncoDiscover® CTC Test - India's first DCG(I) approved blood test that detects circulating tumor cells to reveal early cancer spread before it's visible. Contact Us First name* Last name* Email* Phone* Address Country/Region* Address* City* Zip / Postal code* What are you looking for?* Book a test Other Message* Submit We'd love to help you Whether you want to book a test or want some more information you can fill the form or write to us. Write to us

Explore the latest resources from OncoDiscover® CTC Test, India's first DCG(I) approved blood test that detects circulating tumor cells to reveal early cancer spread before it's visible. Resources Latest from Actorius Explore the latest updates, research perspectives, announcements, and stories shaping our work. Manuscripts Publications Case Study Literature Events 17 March 2026 Publications ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Publications ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Publications ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. Read More 17 March 2026 Publications AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Publications ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. Read More 17 March 2026 Publications AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. Read More 14 March 2026 Press Release Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Read More 9 March 2026 Literature OncoDiscover PD-L1 whitepaper Fighting cancer. One cell at a time. Read More 9 March 2026 Literature OncoDiscover Brochure Detailed Brochure for OncoDiscover Read More 9 March 2026 Literature OncoDiscover TRF Test Requisition Form Read More 7 March 2026 Publications AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. Read More 5 February 2026 Press Release Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Read More 27 January 2026 Manuscript Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... Read More 3 November 2025 Publications PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India. Read More 3 November 2025 Publications Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. Read More 3 November 2025 Publications Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Read More 3 November 2025 Publications Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. Read More First Prev 1 Page 1 Next Last Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

The OncoDiscover® CTC Test is India's first DCG(I) approved blood test that detects circulating tumor cells to reveal early cancer spread before it's visible. Identify CTCs with a simple blood test. Detect the cells before they spread. The OncoDiscover® CTC Test detects circulating tumor cells in the bloodstream using a simple blood sample—helping reveal whether cancer may be spreading before it becomes visible through conventional methods. Book a test A diagnostic test that is patented globally and approved by DCG(I) Know more Requires just 5ml of blood The OncoDiscover® CTC Test requires only 5ml of the patient’s blood sample. Can be done frequently The OncoDiscover® CTC Test can be done at regular intervals for continuous monitoring and arriving at therapy decisions. No exposure to radiation The test is conducted on patient’s blood sample at our diagnostic laboratory. Patients don’t have to go through any physically painful and emotionally stressful tests that use radiations. Convenient. No fasting. Our registered phlebotomists can collect the blood samples from patient’s home. There are no restrictions with regards to fasting or medication for the blood sample. Leading institutions use the OncoDiscover® CTC Test OncoDiscover® CTC Test is being widely accepted by the oncology fraternity and is used for monitoring and effective therapy decisions. Fighting cancer. One cell at a time. One in a billion cells. Even a single tumor cell can cause cancer relapse and can lead to metastasis (spread of cancer). OncoDiscover® CTC Test detects, with pinpoint accuracy, those pesky cells whose presence, even a single one of them, leads to the spread of cancer even after the patient’s treatment has been completed and the patient seems to have recovered. Cost-effective The OncoDiscover® CTC Test has been developed with a goal of making it affordable and accessible to everyone who is in need of it. It is 50% cheaper than any other test to diagnose cancer cells. Time Saving At OncoDiscover® laboratory the diagnostic test are run on the blood samples of the patients. Typically a complete run cycle is completed within a weeks time followed by analysis by scientific experts. Accurate The OncoDiscover® CTC Test can identify pesky tumor cells amongst billions of cells in the blood samples from the patients. It is as accuarate as counting one in a billion cells from the blood sample. Safe The OncoDiscover® CTC Test is absolutely safe. Only 5 ml of patients blood sample is collected and subject to the diagnostic runs. Patients don’t need to through any other tests including that involving radiations. Convenient The OncoDiscover® CTC Test is a simple blood test. Just book the CTC Test online or through a phone call. Our registered phlebotomists can collect the blood samples from patient’s home. Pain-free The patient doesn’t have to go through any medical procedure or go through any tissue biopsy. All that it needs is patients blood samples - ensuring its physically and emotionally pain-free for the patient. Why choose us? Our approach is grounded in rigorous research, advanced platforms, and a commitment to meaningful outcomes. Know more 11000+ Patients Served 450+ Doctors Trust Us 100+ Publications 13+ Years of Excellence Patented Techologies Proprietary innovations designed to deliver precision, reliability, and real-world impact. Regulatory Approved Regulatory-approved solutions built to meet the highest standards of safety, compliance, and clinical integrity. Accreditations/ Patents DCG(I) Approved License No. MFG/IVD/2019/000031 ISO 13485:2016 certified by INTERTEK; Certificate No. 0140783 Innovator of the Year 2019 Department of Biotechnology, Government of India Patented International Application No. PCT/IB2016/050779 Our Publications In collaboration with researchers and thought leaders around the world, OncoDiscover® combines scientific expertise with cutting-edge innovation to advance the frontiers of cancer care. The research behind the technology is supported by 100+ scientific publications presented at leading global forums such as ASCO, AACR, ESMO, ISLB, etc View all publications Latest from Actorius Explore the latest updates, research perspectives, announcements, and stories shaping our work. View all updates Publications ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. 17 March 2026 Read More Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions 17 March 2026 Read More Publications ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers 17 March 2026 Read More OncoDiscover® in Action Stay updated with our latest events, scientific discussions, collaborations, and milestones that continue to shape the future of cancer research and innovation. View all events Events Meet us at AACR 2026 21 March 2026 Read More Events Meeting with our International KOLs 20 February 2026 Read More Events ISLB 2025 | 1-3 November 2025 3 November 2025 Read More Be informed. Be a fighter. Patient Testimonials Hear directly from patients about their experiences and outcomes with our innovations. View all testimonials Sharvari Pantekar Breast Cancer Survivor Rupali Gunjikar Neuro-endocrine Cancer Survivor What’s More Painful than a Cancer Relapse A cancer Relapse not Caught in Time. A cancer Relapse not Caught in Time. A cancer Relapse not Caught in Time. A cancer Relapse not Caught in Time. Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test In the News Explore how OncoDiscover® is making headlines in cancer research and diagnostics. View all mentions Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control 17 March 2026 Read More Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control 17 March 2026 Read More Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control 17 March 2026 Read More © Copyright Actorius Innovations and Research Remission gives you hope. This test gives you confidence. OncoDiscover detects circulating tumour cells early, enabling timely decisions, better control, and renewed confidence. Book a test

Review the Actorius OncoDiscover's terms and conditions governing the use of our website, services, and information related to our oncology research and technologies. Terms & Conditions Date Updated: 03 March 2026 Welcome to the official website of OncoDiscover , a product of Actorius Innovations & Research Pvt. Ltd. , accessible at [https://oncodiscover.com ] (the “Website”). By accessing or using this Website, you agree to comply with and be bound by the following Terms and Conditions. Please review them carefully. 1. Acceptance of Terms By accessing, browsing, or using this Website, you acknowledge that you have read, understood, and agreed to be bound by these Terms and Conditions, along with our Privacy Policy. If you do not agree with any part of these terms, you must discontinue use of the Website immediately. 2. Use of the Website The content on this Website is provided for general informational and educational purposes only and is subject to change without prior notice. You agree to use this Website solely for lawful purposes and in a manner that does not infringe the rights of, restrict, or inhibit the use of this Website by any third party. Any unauthorised use, misuse, or abuse of this Website may give rise to a claim for damages and/or be a criminal offence under applicable Indian laws. 3. Intellectual Property Rights All content on this Website, including but not limited to the OncoDiscover brand, text, graphics, logos, icons, images, illustrations, videos, audio, software, design elements, and data compilations, is the property of Actorius Innovations & Research Pvt. Ltd. or its licensors and is protected by applicable Indian and international intellectual property laws. You may not copy, reproduce, modify, republish, upload, post, transmit, distribute, or exploit any content from this Website in any form or by any means without prior written permission from Actorius Innovations & Research Pvt. Ltd. 4. Third-Party Links This Website may contain links to third-party websites or resources provided for convenience or informational purposes only. Such links do not constitute an endorsement, sponsorship, or recommendation by Actorius Innovations & Research Pvt. Ltd. or OncoDiscover. We have no control over the content, policies, or practices of third-party websites and accept no responsibility or liability for any loss or damage arising from your use of such websites. 5. Disclaimer of Warranties and Limitation of Liability This Website and its content are provided on an “as is” and “as available” basis. Actorius Innovations & Research Pvt. Ltd. makes no representations or warranties, express or implied, regarding the accuracy, completeness, reliability, suitability, or availability of the OncoDiscover Website or its content. To the fullest extent permitted by law, Actorius Innovations & Research Pvt. Ltd. shall not be liable for any direct, indirect, incidental, special, consequential, or exemplary damages, including but not limited to loss of profits, data, goodwill, or other intangible losses, arising out of or in connection with your use of, or inability to use, the Website. Nothing in these Terms shall exclude or limit any liability that cannot be excluded under applicable Indian law. 6. Indemnification You agree to indemnify, defend, and hold harmless Actorius Innovations & Research Pvt. Ltd., its directors, officers, employees, affiliates, partners, agents, and licensors from and against any claims, liabilities, damages, losses, costs, or expenses (including reasonable legal fees) arising from: Your use or misuse of the Website Your violation of these Terms and Conditions Your infringement of any intellectual property or other rights of any third party 7. Governing Law and Jurisdiction These Terms and Conditions shall be governed by and construed in accordance with the laws of India. You agree that any disputes arising out of or relating to these Terms or the use of the Website shall be subject to the exclusive jurisdiction of the courts located in [India – Pune, Maharashtra]. 8. Modifications to Terms Actorius Innovations & Research Pvt. Ltd. reserves the right to revise, modify, or update these Terms and Conditions at any time without prior notice. Any changes will be effective immediately upon posting on the Website. Your continued use of the Website after such changes constitutes acceptance of the revised Terms. 9. Services, Refunds, and Cancellations Where applicable, OncoDiscover services offered by Actorius Innovations & Research Pvt. Ltd., including research, diagnostics, analytics, or related scientific and healthcare solutions, are subject to specific terms communicated at the time of engagement. Due to the specialized and scientific nature of our offerings, refunds or cancellations may be limited or not permitted once a service has commenced, data has been processed, or samples/materials have been analyzed. Any requests for cancellation or refund, where applicable, must be submitted in writing through our official communication channels and will be evaluated on a case-by-case basis. 10. Contact Information If you have any questions, concerns, or requests regarding these Terms and Conditions, please contact us at: OncoDiscover (A product of Actorius Innovations & Research Pvt. Ltd.) Website: https://actorius.com/contact Email: info@actorius.com

Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers Publications 17 March 2026 ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Abstract Background Urological cancers, including prostate, bladder, kidney, testicular, and penile cancers, often fail to show symptoms or show only nonspecific symptoms at early stages. This leads to delayed diagnosis, treatment decisions, and outcomes. Circulating tumor cells (CTCs) predict the outcome in metastatic prostate cancer (PC). Furthermore, in bladder cancer, CTC positivity is linked to muscle invasion, higher recurrence risk, and worse clinical outcomes. CTC PD-L1 expression could evade immune elimination. In spite of complete remission, a higher percentage of patients are known to recur in urothelial cancers. CTCs acting as minimal cellular residual disease (MCRD) are highly implicated, knowing their capacity to be dormant systemically with extravasation and invasion to distant organs. We analyzed the presence of CTCs with PD-L1 over-expression in urological cancers at baseline and follow-ups. Methods Retrospectively, a total of 359 urological cancer patients were evaluated for CTC positivity, including 307 at baseline and 52 follow-up samples. The cancer type distribution was prostate cancer (n = 139), bladder (n = 188), kidney (n = 10), testes (n = 2), penis (n = 8), urothelial (n = 12), etc. Ninety-five percent of the patients were male (n = 293) and 5% were female (n = 14), with most patients aged 61 to 80 years. CTCs expressing PD-L1, positive CTCs, and CTC clusters were analyzed using OncoDiscover® PD-L1 markers and a Zeiss fluorescence automated microscope. Demographics, cancer mean distribution, and CTC and cluster frequency were analyzed. Results Of the 359 patients, CTCs were detected in 68.2% (245/359) of patients, while PD-L1 over-expression on CTCs was present in 49.9% (179/359) of patients. However, CTC clusters were uncommon and occurred in 7.2% (26/359) of patients. Across cancer types (total CTCs = 436), prostate cancer accounted for higher CTCs with a mean CTC distribution of 2.18, while bladder was 0.74, urothelial 0.34, testes 0.18, kidney 0.74, and penis 0.38, respectively. CTC PD-L1 was highest in prostate cancer (46.1%) compared to other cancers, and CTC cluster prevalence was 1.8% in prostate cancer, urothelial (0.9%), and bladder (0.2%) cancers. In CTC-positive cases, 56.3% of patients had only one CTC, 27.8% showed two CTCs, and 8.2% had three. The mean across all patients was 0.6 for CTCs, 0.3 for CTC-PD-L1 positive, and 0.1 for clusters. Conclusions CTCs with PD-L1-positive overexpression were observed across urological cancers, being particularly higher in prostate cancer compared to bladder, kidney, and penis cancers. Many patients are known to recur in spite of complete remission, possibly due to the presence of aggressive CTCs in circulation that could evade the immune system. More studies assessing the presence of CTCs with PD-L1 expression are justified in urological cancers for minimal cellular residual disease and as prognostication. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

PD-L1 expressing CTCs help monitor pancreatic cancer progression and MRD. Publications 25 November 2024 ISLB 2024: Expression of Programmed Death - Ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients CTC detection with PD-L1 overexpression reveals aggressive pancreatic cancer and potential biomarker value for monitoring metastasis and disease progression. Introduction Pancreatic cancer shows a high mortality rate due to difficulties in early diagnosis and the absence of standardized guidelines for assessing suspicious pancreatic masses. Biomarkers such as carcinoembryonic antigen (CEA) and CA19-9 lack sufficient sensitivity and specificity for pancreatic cancer detection. While tissue biopsy provides a static signature of target protein expressions, including PD-L1, the enumeration and profiling of circulating tumor cells (CTCs) with cell surface markers can offer actionable targets for treatment. We present findings in pancreatic cancer where CTCs are associated with overexpression of PD-L1 as a dynamic marker for monitoring minimal residual disease (MRD) and disease progression, highlighting its role in the metastatic cascade. Methods Retrospectively, 50 pancreatic cancer patients were investigated for the presence of CTCs. Among them, 12 patients (24%) were in the early stage of disease, with ages ranging from 35 to 75 years. Sixty percent of patients were male (n = 30) and 40% were female (n = 20), while 76% (n = 38) were classified as late-stage cases. PD-L1 expression was evaluated using the approved OncoDiscover platform, which utilizes multi-component systems conjugated with anti-EpCAM antibodies on magnetic nanoparticles. CTC enumeration was performed using CD45–, EpCAM+, DAPI+, and CK18+ markers in 1.5 ml of peripheral blood. Functional assays assessed PD-L1 overexpression on CTCs using automated motorized Zeiss fluorescence microscopy. The sensitivity of the CTC and PD-L1 assay had been previously evaluated in other solid cancers. Results Out of 50 pancreatic cancer patients, 74% (n = 37) had at least one detectable CTC. Among these patients, 51% (n = 19) had one CTC, 30% (n = 11) had two CTCs, 14% (n = 5) had three CTCs, and 5% (n = 2) had four CTCs. The mean number of CTCs and clusters was 1.28 and 0.16, respectively. Additionally, 92% (n = 34) of patients demonstrated PD-L1 expression on CTCs. CTC clusters were observed in 19% of patients (n = 7). The mean PD-L1 expression on CTCs was 1.14. Conclusions CTCs with PD-L1 overexpression strongly suggest poor prognosis, potentially linked to activation of the metastatic cascade through immune system evasion. Larger studies are required to validate whether PD-L1-positive CTCs can serve as a reliable biomarker for the diagnosis and management of pancreatic cancer. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Chemo-specific designs for the enumeration of CTCs: advances in liquid biopsy Manuscript 18 December 2020 Manuscript: Chemo-specific designs for the enumeration of circulating tumor cells: advances in liquid biopsy Review on chemo-specific nano/micro substrates for efficient CTC isolation, enabling liquid biopsy, metastasis detection, and real-time cancer monitoring. Advanced materials and chemo-specific designs at the nano- and micrometer scale have ensured revolutionary progress in next-generation clinically relevant technologies. For example, isolating a rare population of cells, such as circulating tumor cells (CTCs) from blood among billions of other blood cells, is one of the most complex scientific challenges in cancer diagnostics. Achieving this level of exceptional specificity for extracellular biomarker interactions requires chemical tunability through the use of advanced materials and multistep reactions in both solution and insoluble states. This review delineates the chemo-specific substrates, chemical methods, and structure–activity relationships (SARs) of chemical platforms used for the isolation and enumeration of CTCs, thereby advancing the relevance of liquid biopsy in cancer diagnostics and disease management. We highlight the synthesis of cell-specific, tumor biomarker-based chemo-specific substrates utilizing functionalized linkers through chemistry-based conjugation strategies. The capacity of these nano- and micro-scale substrates to enhance interaction specificity and efficiency with targeted tumor cells is discussed in detail. Furthermore, this review emphasizes the importance of CTC capture and downstream processes involving genotypic and phenotypic CTC analysis in real time. These approaches enable early detection of metastasis progression, evaluation of chemotherapy treatment response, and monitoring of progression-free survival (PFS), disease-free survival (DFS), and overall survival (OS) in cancer patients. Royal Society of chemistry. View Manuscript Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

CTC and PD-L1 profiling supports therapy stratification and monitoring in cancers. Publications 16 September 2025 PD-L1 overexpression on circulating tumor cells and CTC clusters: A potential biomarker across solid carcinomas Correlation of CTC detection, PD-L1 expression, and CTC clusters highlights biomarkers for minimal residual disease and cancer progression monitoring. Abstract Background Overexpression of the dynamic protein PD-L1 on circulating tumor cells (CTCs) is a highly implicative biomarker that represents post–curative intent status, minimal residual disease (MRD), disease aggressiveness, therapeutic response, and metastatic progression. We evaluated the correlation among CTC detection, PD-L1 expression, and CTC clusters present in solid tumors, namely lung, breast, colorectal, ovarian, and prostate carcinomas. Longitudinal monitoring of CTCs remains a major focus after treatments, including surgical intervention with curative intent. Methods Retrospectively, we analyzed 328 cancer patients (male 163, female 165) across stages, consisting of a total of 383 samples with baseline and follow-ups (n = 55). Cancer types included lung (27.13%), colorectal cancer (21.95%), breast (9.75%), ovary (4.2%), prostate (3.9%), and others. CTCs and clusters were detected from 1.5 ml peripheral blood using the OncoDiscover platform approved by the Central Drugs Standard Control Organization of India. The platform contains a multifunctional magneto-nanosystem mediated by anti-epithelial cell adhesion molecule (EpCAM) antibody. CTCs were confirmed as EpCAM+ve, CK18+ve, DAPI+ve, and CD45–ve. PD-L1 expression on CTCs was detected based on the linear intensity gradients of fluorescence signals using image acquisition on an automated fluorescence microscope. Results Among the 383 samples with baseline and follow-ups, 69.45% of patients had CTCs ranging from 1–11. Approximately 77% of patients were above the age of 50. The total number of CTCs observed was ~649 with a mean distribution of ~1.69. CTCs with PD-L1 overexpression were observed in 55.35% of patients (n = 266). Higher CTC prevalence was observed in lung cancer (24.75%), followed by colorectal cancer (21.57%) and breast cancer (5.89%). CTC clusters were observed in 10.18% of patient samples. Notably, concurrent positivity for both CTCs and PD-L1 expression was most prevalent in lung cancer patients, suggesting a potential aggressive disease phenotype and therapeutic vulnerability. Conclusions The findings support the integrated use of CTCs and their PD-L1 expression as a composite biomarker strategy to stratify patients for targeted therapies, immunotherapeutic interventions, and longitudinal monitoring. View Publication Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

OncoDiscover Brochure Literature 9 March 2026 OncoDiscover Brochure Detailed Brochure for OncoDiscover Download Brochure Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test

Self-propelled CNT microrockets enable rapid capture and isolation of CTCs. Manuscript 13 April 2015 Manuscript: Self-propelled Carbon Nanotube Based Microrockets for Rapid Capture and Isolation of Circulating Tumor Cells Self-propelled CNT microrockets rapidly capture and magnetically isolate circulating tumor cells, enabling faster liquid biopsy and early cancer detection. We demonstrated a novel carbon nanotube (CNT)-based microrocket that propels efficiently through the thrust generated by oxygen (O₂) bubbles. These self-propelled microrockets exhibit ultrafast propulsion in aqueous solutions as well as in Dulbecco’s modified Eagle’s medium (DMEM). The microrocket generated a driving force of over 231 and 300 pN in DMEM containing 4% hydrogen peroxide (H₂O₂). The speed and distance traveled by the microrocket can be controlled by adjusting the concentration of H₂O₂. The designed multifunctional microrocket has the ability to (i) rapidly target (~5 minutes) and efficiently capture (~85%) transferrin receptor–positive (TfR⁺) cancer cells from an artificial CTC-like suspension, (ii) magnetically isolate the captured cells from peripheral blood cells, and (iii) enable subsequent high-resolution imaging. We envision that such self-powered micromotors could provide a novel and effective approach for the rapid and efficient extraction of circulating tumor cells (CTCs) from biological fluids, supporting early cancer diagnosis and detection of recurrence. View Manuscript Never Miss a Breakthrough. Get the latest news and innovations from OncoDiscover delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe Early detection is half the battle won. Book a Test Simply book a CTC Test online or over a phone call and schedule a visit by our registered phlebotomists. Sample Collection Upon booking the CTC Test, one of our registered phlebotomists shall visit and collect 10 ml of patient’s blood sample. Receive Report A set of diagnostics will be run on the patient’s blood sample and the report shall be provided in 7 working days upon receipt of sample on site. Book a test